Bristol Myers Squibb has jettisoned another cancer candidate in-licensed under its former CEO. Immatics is the latest partner ...

An American Depositary Receipt (ADR) is a certificate issued by a U.S. bank that represents shares of a foreign company.

Shares of Immatics (IMTX) have gained 1.2% over the past four weeks to close the last trading session at $12.52, but there could still be a solid upside left in the stock if short-term price ...

"ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific" was originally created and published by Clinical ...

Immatics (NASDAQ:IMTX) just reported results for the second quarter of 2024. Immatics reported earnings per share of -18 cents. This was above the analyst estimate for EPS of -31 cents.

Immatics (NASDAQ: IMTX), a clinical-stage biopharmaceutical company, maintained its Outperform rating and $16.00 price target from Mizuho. The affirmation follows recent developments including the ...

IMMATICS is a leader in developing targeted therapies that enable the immune system to recognize and destroy cancer cells. Their innovative approaches, based on personalized TCR-T cell therapies ...

Bristol Myers Squibb presented the positive Phase III results on its already approved Opdivo-Yervoy combo at ESMO over the ...

Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery ...

Cancer biotech Immatics has begun a collaboration with GlaxoSmithKline to develop novel therapies built around its T-cell-based technology. The partnership with the big UK pharma will focus on ...

Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...

Immatics (NASDAQ: IMTX), a clinical-stage biopharmaceutical company, maintained its Outperform rating and $16.00 price target from Mizuho. The affirmation follows recent developments including the ...